GMP in Pharmaceutical Gelatin Production: Standards That Protect Your Product

A pharmaceutical manufacturer discovers during a supplier audit that their gelatin supplier cannot produce a TSE/BSE declaration traceable to the species and country of origin of the raw material. The batch is on hold. The regulatory submission is delayed. The root cause was not a quality failure in the gelatin itself — it was a documentation failure in the supply chain.

This scenario is more common than the industry acknowledges. Good Manufacturing Practice (GMP) for pharmaceutical gelatin is not primarily about product chemistry. It is about the system surrounding that chemistry: who audits it, how often, what records are generated, and whether those records will hold up under regulatory scrutiny.

For procurement managers, QA directors, and formulation scientists evaluating porcine gelatin suppliers, this article explains what GMP compliance actually requires of a gelatin manufacturer, how the major certification standards relate to each other, and what documentation a supplier must be able to provide before you can qualify them.

What GMP Means in the Context of Gelatin Production

Good Manufacturing Practice, in its pharmaceutical interpretation, refers to the system of controls — over premises, equipment, personnel, processes, testing, and documentation — that ensures a product is consistently produced and controlled according to defined quality standards.

In the EU, GMP for licensed medicinal product manufacturers is codified in EudraLex Volume 4. For excipient suppliers — including gelatin manufacturers — the applicable framework is the EU Commission's Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate GMP for excipients, which references EudraLex Volume 4 as a baseline and requires pharmaceutical manufacturers to carry out a risk-based GMP assessment for each excipient supplier. The appropriate GMP level depends on the excipient's risk classification; it is not automatically identical to full EudraLex Part I requirements.

Gelatin is classified as a pharmaceutical excipient when used in gelatin capsule shells — whether hard gelatin capsules (HGCs) or soft gelatin capsules (SGCs). The European Pharmacopoeia monograph Ph. Eur. 0330 defines the quality standards that gelatin must meet for pharmaceutical use, including specifications for Bloom strength, viscosity, moisture content, sulphur dioxide (≤50 ppm), heavy metals, and microbiological quality. These are mandatory minimum parameters; compliant suppliers provide lot-specific data against each one.

What GMP controls in a gelatin manufacturing facility in practice:

1. Raw material control — verification of species, geographic origin, and veterinary supervision of source slaughterhouses; TSE/BSE risk assessment per incoming lot
2. Production environment — hygiene monitoring, segregation of in-process material, prevention of cross-contamination between grades
3. Process validation — documented evidence that the extraction, concentration, and drying steps consistently produce product within specification
4. Batch testing — chemical and microbiological analysis per lot, against defined specifications, by qualified laboratory personnel
5. Traceability systems — linking every finished product lot to specific raw material batches, with records retained for defined periods 
6. Out-of-specification (OOS) management — documented investigation procedures when any parameter falls outside specification, with root cause analysis and corrective action
7. Change control — formal approval process before any change to raw material sourcing, production process, or specification

A supplier that cannot demonstrate documented compliance with all seven control areas is not GMP-ready for pharmaceutical supply, regardless of what their marketing materials claim.

Key Standards: What Each Covers and How They Relate

Several certification frameworks appear in pharmaceutical gelatin supplier qualification processes. They are related but not interchangeable — understanding the hierarchy matters for your QA team.

EU GMP / EudraLex Volume 4 is the regulatory baseline for licensed medicinal product manufacturers. Excipient suppliers are assessed against it indirectly, through the risk-based framework described above. Direct EU GMP inspection of an excipient supplier is possible under EU Directive 2011/62/EU (the Falsified Medicines Directive) for certain product categories.

EXCiPACT is the dedicated certification scheme for pharmaceutical excipient suppliers, developed by IPEC Europe, IPEC-Americas, the Pharmaceutical Quality Group (PQG), the European Fine Chemicals Group (EFCG), and the European Association of Chemical Distributors (FECC). Based on the IPEC-PQG GMP Guide, it provides demonstrable evidence that a supplier has implemented GMP appropriate for pharmaceutical excipient production. It is the standard most directly aligned with excipient GMP requirements as distinct from food safety standards.

BRCGS Food Safety Issue 9 is a comprehensive food safety and quality management standard, GFSI-benchmarked and audited by independent certification bodies. Grade AA — the highest achievable grade — requires no more than five minor non-conformities, zero major, and zero critical at audit. BRCGS is not a pharmaceutical GMP standard, but Grade AA is widely referenced in supplier qualification processes as evidence of strong operational controls. The BRCGS Issue 9 scheme, mandatory from February 2023, introduced a requirement for a mandatory unannounced audit at least once every three years, meaning certified sites must maintain quality systems at audit-ready level as a matter of daily operations.

ISO 22000:2018 covers food safety management across the supply chain, using a HACCP-based approach. It underpins BRCGS and is required in most food and nutraceutical supply chains. Its 3-year certification cycle includes annual surveillance audits. 

ISO 9001:2015 provides the quality management system framework — process approach, continuous improvement, customer focus — and is required alongside ISO 22000 in most pharmaceutical and nutraceutical supplier qualification frameworks.

Important distinction: BRCGS and ISO 22000 are food safety standards. For licensed medicinal products, they do not substitute for pharmaceutical GMP requirements under EudraLex or for dedicated excipient GMP frameworks such as EXCiPACT. Buyers should confirm the appropriate qualification standard with their regulatory affairs team for their specific product category and target market.

How Certification Is Audited — and What It Proves

BRCGS and ISO certification is issued by accredited, independent certification bodies following a structured on-site audit. Certification is not self-declared. The certification body examines: documentation and records, production facility and equipment, personnel competence and training records, raw material controls, traceability systems, HACCP plan validity, and the corrective action history from previous non-conformances.

BRCGS Issue 9's unannounced audit requirement raises the bar compared to purely announced programmes. Sites that participate in the unannounced programme cannot prepare specifically for an audit day; the quality system must function consistently as the daily operating standard. The result is a stronger evidence base for buyers who need confidence that a supplier's systems work on ordinary production days, not only under observation.

Documentation Buyers Should Receive — and What Each Means

A compliant pharmaceutical gelatin supplier should be able to provide the following documentation on request. If any item requires significant lead time or escalation, treat that as a risk signal.

1. Certificate of Analysis (CoA) — per production lot Must include: Bloom strength (grams, measured by standardised bloom gelometer method), viscosity (mPa·s at 6.67% w/w, 60°C), moisture/loss on drying, ash content, pH, sulphur dioxide, heavy metals (lead, arsenic, cadmium, mercury), total aerobic microbial count, absence of specified pathogens (Salmonella, E. coli). Lot-specific values, not specification ranges alone.

2. TSE/BSE Declaration — per delivery or per lot A signed, dated document confirming: animal species of raw material origin (for porcine gelatin: Sus scrofa domesticus), anatomical tissue type (hides and skins), country of origin of source animals, and a statement of compliance with EU Regulation (EC) No 999/2001 or equivalent. Porcine gelatin carries an inherently lower TSE risk profile than bovine gelatin, since no natural susceptibility to BSE has been demonstrated in pigs, but the declaration is still a mandatory documentation requirement for pharmaceutical dossiers.

3. Country-of-Origin Certificate Confirming the geographic source of raw material — relevant for regulatory submissions and for buyer traceability requirements.

4. Allergen Declaration Confirming allergen status under EU Regulation (EC) No 1169/2011. Gelatin derived from pork is not a listed allergen under EU law, but a formal declaration is required for buyer documentation systems.

5. Current Certifications With issuing body name, audit date, expiry date, and scope clearly stated. BRCGS certificates should be cross-checked against the public BRCGS Directory.

6. Technical Data Sheet / Product Specification Sheet Defining the committed specification for Bloom grade, viscosity, particle size, and intended application (food, pharmaceutical, cosmetic).

Conclusion

Choosing a pharmaceutical gelatin supplier on compliance grounds requires understanding what each certification standard actually covers, what the audit cycle proves, and whether the documentation the supplier provides will hold up under regulatory scrutiny — in your own QA system and, ultimately, in a submission dossier.

The hierarchy runs from food safety standards (ISO 22000, BRCGS) through dedicated excipient GMP frameworks (EXCiPACT, based on the IPEC-PQG GMP Guide) to full pharmaceutical GMP (EudraLex Volume 4). The appropriate level depends on your product category, target market, and the risk classification of gelatin in your formulation. No certification logo answers that question on its own.

If you are evaluating porcine gelatin suppliers for pharmaceutical or nutraceutical applications, contact Brodnica Gelatin's technical team to discuss certification documentation and qualification requirements.

Sources

1. European Pharmacopoeia (Ph. Eur.) — Gelatin monograph 0330. Defines quality parameters for pharmaceutical-grade gelatin: Bloom strength, viscosity, sulphur dioxide (≤50 ppm), heavy metals, microbiological quality, and pH. Measurlabs reference: https://measurlabs.com/products/pharmaceutical-raw-material-analyses--ph-eur-monographs/
2. Pharma Excipients / pharmaexcipients.com — "Gelatin as Pharmaceutical Excipient". Overview of USP-NF and Ph. Eur. monograph requirements; critical quality attributes for pharmaceutical gelatin in capsule manufacturing. https://www.pharmaexcipients.com/gelatin-as-excipient/
3. Pharmaceutical Technology / pharmtech.com — "Ensuring Quality in Pharmaceutical Raw Materials" (Capsugel / Jean-Philippe Talmon). Over 15 regulatory references govern global gelatin purchasing specifications; critical-to-quality attributes for capsule gelatin; heavy metal limits revised after 2012 chromium incident in Chinese capsule supply chain. https://www.pharmtech.com/view/ensuring-quality-pharmaceutical-raw-materials-2
4. EU Commission — Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate GMP for excipients of medicinal products for human use (2015/C 95/02). Legal basis for excipient GMP requirements in the EU; risk-based framework for classifying excipients and determining appropriate GMP level. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0321(02)
5. EXCiPACT — Certification Standards for Pharmaceutical Excipient Suppliers. Dedicated GMP/GDP certification scheme for excipient suppliers, developed by IPEC Europe and PQG; based on IPEC-PQG GMP Guide; aligned with ISO 9001:2015. SGS overview: https://www.sgs.com/en/news/2019/07/excipact-certification-standards-for-pharmaceutical-excipient-suppliers-gmp-and-gdp
6. BRCGS grading system — multiple sources. Grade AA = ≤5 minor non-conformities, zero major, zero critical; Issue 9 mandatory from 1 February 2023; mandatory unannounced audit cycle every three years under Issue 9. Sources: https://cpdonline.co.uk/knowledge-base/food-hygiene/brcgs-definition/ · https://documentcompliance.com/brcgs-audit-checklist-for-food-manufacturing/ · https://www.fooddocs.com/post/brc
7. BRCGS Issue 9 — QIMA overview. Unannounced audit protocol under Issue 9; announced, blended, and unannounced audit programme options; 12-month certificate validity; Grade D triggers 28-day follow-up audit. https://blog.qima.com/brcgs/navigating-brcgs-issue-9
8. European Medicines Agency (EMA) — "Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products" (scientific guideline). EMA guidance on TSE/BSE risk management for pharmaceutical excipients including gelatin. https://www.ema.europa.eu/en/minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-human-veterinary-medicinal-products-scientific-guideline
9. EUR-Lex / European Commission — Regulation (EC) No 999/2001 (TSE Regulation). Legal basis for TSE/BSE controls on animal-derived products including gelatin in the EU. https://eur-lex.europa.eu/EN/legal-content/summary/transmissible-spongiform-encephalopathies-tses.html
10. EFSA Journal (2024) — "BSE risk posed by ruminant collagen and gelatine derived from bones". Porcine gelatin regulatory context under EU Regulation 999/2001; distinction between porcine and bovine gelatin in TSE risk frameworks. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2024.8883